Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 1, 2013, Pages 11-18

  Manousaridis, I ^a   Mavridou, S ^a   Goerdt, S ^a   Leverkus, M ^a   Utikal, J ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 [4 (1 HYDROXYIMINO 5 INDANYL) 3 (4 PYRIDINYL) 1H PYRAZOL 1 YL]ETHANOL; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; AMMONIUM LACTATE; CLINDAMYCIN; CLOBETASOL; DABRAFENIB; DACARBAZINE; DOXYCYCLINE; ERYTHROMYCIN; FAMOTIDINE; ISOTRETINOIN; METRONIDAZOLE; MINOCYCLINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MOMETASONE FUROATE; NADIFLOXACIN; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNICARBATE; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; SELUMETINIB; SORAFENIB; TRAMETINIB; UNINDEXED DRUG; VEMURAFENIB; XL 281;

ALOPECIA; ANTIBIOTIC PROPHYLAXIS; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG TOLERABILITY; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; FATIGUE; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; HYPERKERATOSIS; KERATOACANTHOMA; MELANOMA; METASTATIC MELANOMA; NAUSEA; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; REVIEW; SALVAGE THERAPY; SIGNAL TRANSDUCTION; SKIN CARCINOMA; SKIN DISEASE; TREATMENT RESPONSE; XEROSIS;

ANTINEOPLASTIC AGENTS; DRUG ERUPTIONS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENES, RAS; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROGNOSIS; PROTEIN KINASE INHIBITORS; RAF KINASES; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84872857932     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04546.x     Document Type: Review

References (65)

1. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
2. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003; 95: 625-627.
3. Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RASBRAF signaling pathway in papillary thyroid carcinoma. Cancer 2003; 63: 1454-1457.
4. Platz A, Egyhazi S, Ringborg U, et al. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol 2008; 1: 395-405.
5. Karasarides M, Chiloeches A, Hayward R, et al. B-RAF is a therapeutic target in melanoma. Oncogene 2004; 23: 6292-6298.
6. Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a Phase-II randomised discontinuation trial analysis. Br J Cancer 2006; 5: 120-130.
7. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109.
8. Arkenau HT, Kefford R, Long GV,. Targeting BRAF for patients with melanoma. Br J Cancer 2011; 104: 392-398.
9. Schwartz GK, Robertson S, Shen A, et al. A phase-I study of XL281, a selective oral RAF kinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2009; 27: 15s (abstract 3513).
10. Flaherty KT, Lee SJ, Schuchter LM, et al. Final results of E2603: a double blind, randomized phase-III trial comparing carboplatin/paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol 2010a; 28: 5s (abstract 8511).
11. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010b; 363: 809-819.
12. Chapman PB, Hauschild A, Robert C, et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. N Engl J Med 2011; 364: 2507-2516.
13. Kefford R, Arkenau H, Brown MP, et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 2010; 28: 15s (abstract 8503).
14. Rinehart J, Adjei AA, Lorusso PM, et al. Multicenter phase II study of the oral MEK-inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004; 22: 4456-4462.
15. Ribas A, Kim KB, Schuchter LM, et al. BRIM-2: an open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. J Clin Oncol 29: 2011 (suppl; abstr 8509).
16. Trefzer U, Minor D, Ribas A, et al. BREAK-2: a phase IIA trial of the selective BRAF kinase inhibitor GSK2118436 in patients with BRAF mutation-positive (V600E/K) metastatic melanoma. Pigment Cell Res 2011; 24: 990-1075 (abstract LBA1-1).
17. Lorusso PM, Adjei AA, Varterasian M, et al. Phase I and pharmacodynamic study of the oral MEK-inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005; 23: 5281-5293.
18. Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008; 26: 2139-2146.
19. Banerji U, Camidge DR, Verheul HM, et al. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res 2010; 16: 1613-1623.
20. Desar IM, Bovenschen HJ, Timmer-Bonte AJ, et al. Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours. Acta Oncol 2010; 49: 110-113.
21. Kim KB, Lewis K, Pavlick A, et al. A phase II study of the MEK1/MEK2 inhibitor GSK1120212 in metastatic BRAF-V600E or K mutant cutaneous melanoma patients previously treated with or without a BRAF inhibitor. Pigment Cell Res 2011; 24: 990-1075 (abstract LBA1-3).
22. Infante JR, Falchook GS, Lawrence DP, et al. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). J Clin Oncol 29: 2011 (suppl; abstr CRA8503).
23. Flaherty K, Infante JR, Falchook GS, et al. Phase I/II expansion cohort of BRAF inhibitor GSK2118436 + MEK inhibitor GSK1120212 in patients with BRAF mutant metastatic melanoma who progressed on a prior BRAF inhibitor. Pigment Cell Res 2011; 24: 990-1075 (abstract LBA1-4).
24. Gutzmer R, Becker JC, Enk A, et al. Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician. J Dtsch Dermatol Ges 2011; 9: 195-203.
25. Balagula Y, Lacouture ME, Cotliar JA,. Dermatologic toxicities of targeted anticancer therapies. J Support Oncol 2010; 8: 149-161.
26. Querfeld C, Duffy K, Magel G, et al. Disseminated follicular eruption during therapy with the MEK-inhibitor AZD6244. J Am Acad Dermatol 2011; 64: e17-e19.
27. Guttman-Yassky E, Mita A, De Jonge M, et al. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. Eur J Cancer 2010; 46: 2010-2019.
28. Khavari TA, Rinn J,. Ras/Erk MAPK signaling in epidermal homeostasis and neoplasia. Cell Cycle 2007; 6: 2928-2931.
29. Kern F, Niault T, Baccarini M,. Ras and Raf pathways in epidermis development and carcinogenesis. Br J Cancer 2011; 104: 1240.
30. Karnoub AE, Weinberg RA,. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008; 9: 517-531.
31. Galabova-Kovacs G, Matzen D, Piazzolla D, et al. Essential role of B-Raf in ERK activation during extraembryonic development. Proc Natl Acad Sci USA 2006; 103: 1325-1330.
32. Meier FE, Beck D, Niessner H, et al. Induction of apoptosis by the BRAFV600E kinase inhibitor PLX4032 in BRAFV600E melanoma cells through regulation of endoplasmic reticulum stress-related genes. J Clin Oncol 29: 2011 (suppl; abstr 8518).
33. Deng M, Chen WL, Takatori A, et al. A role for the mitogen-activated protein kinase kinase kinase 1 in epithelial wound healing. Mol Biol Cell 2006; 17: 3446-3455.
34. Peric M, Koglin S, Dombrowski Y, et al. VDR and MEK-ERK dependent induction of the antimicrobial peptide cathelicidin in keratinocytes by lithocholic acid. Mol Immunol 2009; 46: 3183-3187.
35. James WD, Berger TG, Elston DM, eds. Nutritional Diseases. In ANDREWS' Diseases of the skin (pp 479-486). Elsevier 2006.
36. Robert C, Arnault JP, Mateus C,. RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol 2011; 23: 177-182.
37. Lacouture M, Chapman P, Ribas A, et al. Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy. J Clin Oncol 29: 2011 (suppl; abstr 8520).
38. Su F, Viros A, Milagre C, et al. RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors. N Engl J Med 2012; 366: 207-215.
39. Oberholzer PA, Kee D, Dziunycz P, et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012; 30: 316-321.
40. Lemech C, Arkenau HT,. Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities. Clin Med Insights Oncol 2012; 6: 53-66.
41. Degen A, Alter M, Schenck F, et al. Cutaneous side effects of medical tumor therapy. Hautarzt 2011; 62: 444-445.
42. Balagula Y, Barth Huston K, Busam KJ, et al. Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). Invest New Drugs 2011; 29: 1114-1121.
43. Reck M, Gutzmer R,. Management of the cutaneous side effects of therapeutic epidermal growth factor receptor inhibition. Onkologie 2010; 33: 470-479.
44. U. S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.02-2009- 09-15-QuickReference-5x7.pdf (last accessed: 22 May 2010).
45. Lynch TJ Jr, Kim ES, Eaby B, et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007; 12: 610-621.
46. Lacouture M, Cotliar J, Mitchell E,. Clinical management of EGFRI dermatologic toxicities: US perspective. Oncology. 2007a; 21 (Suppl. 5): 17-21.
47. Lacouture M, Melosky BL,. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective. Skin Therapy Lett 2007b; 12: 1-5.
48. Pérez-Soler R, Delord JP, Halpern A, et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005; 10: 345-356.
49. Segaert S, Van Cutsem E,. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425-1433.
50. Melosky B, Burkes R, Rayson D, et al. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol 2009; 16: 16-26.
51. Wollenberg A, Moosmann N, Kroth J, et al. Therapie schwerer akneiformer Cetuximab-Exantheme mit oralem Retinoid, topischem Antibiotikum und Steroidexternum. Hautarzt 2007; 58: 615-618.
52. Hu JC, Sadeghi P, Pinter-Brown LC, et al. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 2007; 56: 317-326.
53. Galimont-Collen AF, Vos LE, Lavrijsen AP, et al. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer 2007; 43: 845-851.
54. Scope A, Agero AL, Dusza SW,. Randomized double-blind trial of prophylactic oral minocyclin and tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007; 25: 5390-5396.
55. Lacouture ME, Mitchell EP, Piperdi B,. Skin toxitcity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patitents with metastastic colorectal cancer. J Clin Oncol 2010; 28: 1351-1357.
56. Deplangue G, Chavaillon J, Vergnenegre A,. CYTAR: a randomized clinical trial evaluating the preventive effect of doxycycline on erlotinib-induced folliculitis in non-small cell lung cancer patients. J Clin Oncol 2008 28: 15s (abstr 9019).
57. Jatoi A, Rowland K, Sloan JA, et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 2008; 113: 847-853.
58. Wu X, Nguyen BC, Dziunycz P, et al. Opposing roles for calcineurin and ATF3 in squamous skin cancer. Nature 2010; 465: 368-372.
59. Thaçi D, Salgo R,. Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies. Clin Dermatol 2010; 28: 52-56.
60. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
61. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
62. Arnault JP, Wechsler J, Escudier B, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 2009; 27: e59-e61.
63. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6: 491-500.
64. Shu KY, Kindler HL, Medenica M, et al. Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. Br J Dermatol 2006; 154: 191-192.
65. Hammond-Thelin LA,. Cutaneous reactions related to systemic immunomodulators and targeted therapeutics. Dermatol Clin 2008; 26: 121-159.